Redeye updates its view on Better Collective post its Q1-results which was in line with expectations...
Cantargia’s Q122 results were in line with our expectations.
While the Q1 report offered few surprises, the Novartis subset analysis of CANOPY-1 was an important...
BankNordik raised its 2022 net profit guidance by ~20%, up to DKK 160-190m, from DKK 130-160m previo...
Redeye comments on Cantargia's Q1 report 2022.
Kiliaro startade 2022 med att fortsätta växa användarbasen som fortsatt är bolagets primära målsättn...
Order från Google Fiber i USA fortsätter att utvecklas väl för InCoax del.
Redeye comments on ISAB’s Q1’22 report. The company has seen a continued high interest for its IRS b...
Leveranser till Nyttobostäder Nettoomsättningen i Q1'22 uppgick till 895 mkr (173 mkr i Q1'21), driv...
Following the completion of the first clinical Proof-of-Principle (PoP) study in the IPTN2021 progra...
Redeye lowers its estimates because of the slow Q1 and due to uncertainty about the big Russian orde...
Stigande energipriser och tydligare behov av energiomställning driver efterfrågan för havsbaserad vi...
Investmentbolaget MTIs har utvecklats positivt trots senaste tiden som har kantats av omvärldsoro oc...
Q1 NOI +4% vs ABGSCe Interest rate expectations driving CEPS-revisions 2023 P/CEPS of ~12x, fair val...
Impressive start to the year Positive revisions due to core business and M&A Three new promising gam...
AcouSort publicerade den 18 maj 2022 sin delårsrapport för Q1-22.
Redeye gives a short comment on today’s update on the approval process for Tesofensine in Mexico.
Redeye is encouraged to learn that ISR has signed an agreement with Gerresheimer for clinical-scale ...
Redeye updates its estimates for 2022, following reviews of the quarterly report, the company’s prod...
Rekordtillväxt och nya kunder... Omsättningen i Q1'22 blev 15,8 mkr vs vårt estimat om 14,7 mkr, vil...
